Evidence map›Paper›PMID 10980850›Full record

ReviewCurrent cardiology reports1999

Inflammation and lipid-lowering treatment.

C M Ballantyne, Y Abe

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current cardiology reports, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 59% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

C M BallantyneDepartment of Medicine, Baylor College of Medicine, 6565 Fannin, MS A-601, Houston, Texas 77030, USA.
Y Abe
Baylor College of Medicine · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Leukocytes play a critical role in both the initial steps of atherogenesis and the late events of plaque instability and thrombosis. Leukocyte-endothelial cell adhesion molecules (CAMs) modulate the interaction between circulating leukocytes and the vessel wall. Levels of soluble CAMs are increased in patients with dyslipidemia or other risk factors, and levels can be reduced by lipid-modifying therapy. Novel markers of inflammation and atherosclerosis may be useful to identify high-risk individuals and to assess the efficacy of antiatherosclerotic therapy.

Indexed as

BiomarkersCell Adhesion MoleculesHumansHyperlipidemiasHypertriglyceridemiaHypolipidemic AgentsInflammationIntercellular Adhesion Molecule-1Risk FactorsVascular Cell Adhesion Molecule-1BiomarkersCell Adhesion MoleculesHypolipidemic AgentsIntercellular Adhesion Molecule-1Vascular Cell Adhesion Molecule-1

Identifiers

PMID10980850
OpenAlexW2064513436

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.